Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | The value of using personalized approaches when treating patients with MF

Elisabetta Abruzzese • 24 Oct 2022
SOHO Italy 2022
Myelofibrosis Myeloproliferative Neoplasms

Elisabetta Abruzzese, MD, PhD, St Eugenio University Hospital, Rome, Italy, briefly comments on the use of JAK2 inhibitors in myelofibrosis (MF), and further highlights the value of combining novel agents and using more personalized approaches when treating these patients. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elisabetta Abruzzese

5:18
Investigating the outcomes of children born to patients with CML
Elisabetta Abruzzese • 11 Dec 2023
4:32
Patients with Ph+ CML entering TFR in pregnancy: a sub-analysis of the Italy TFR registry
Elisabetta Abruzzese • 11 Dec 2023
5:35
Situations that may arise with CML during pregnancy & management strategies
Elisabetta Abruzzese • 8 Sep 2023
9:13
CML during pregnancy: implications and considerations for treatment
Elisabetta Abruzzese • 8 Sep 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals